dipyridamole has been researched along with Central Nervous System Disease in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dipyridamole was introduced on the market as coronary vasodilator drug more than half a century ago and is still used as antithrombotic and vasodilator." | 2.52 | Dipyridamole: a drug with unrecognized antioxidant activity. ( Ciacciarelli, M; Iuliano, L; Violi, F; Zerbinati, C, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ciacciarelli, M | 1 |
| Zerbinati, C | 1 |
| Violi, F | 1 |
| Iuliano, L | 1 |
1 review available for dipyridamole and Central Nervous System Disease
| Article | Year |
|---|---|
Dipyridamole: a drug with unrecognized antioxidant activity.
Topics: Animals; Antioxidants; Cardiovascular Diseases; Central Nervous System Diseases; Dipyridamole; Drug | 2015 |